文献速递前列腺增生与排尿功能障碍前列腺癌

前列腺癌预防试验中267,983人年随访未发现非那雄胺后综合征证据

No Evidence of Post-Finasteride Syndrome in 267,983 Person-Years Follow-up in the Prostate Cancer Prevention Trial.
PubMed 文献 · Urology · 2026-08-22

本研究将前列腺癌预防试验(PCPT)受试者记录与Medicare理赔数据链接,评估非那雄胺后综合征(PFS)相关22种症状的频率。在267,983人年随访中,未发现任何症状与治疗组存在统计学显著关联,不支持PFS概念。

要点

  • PCPT长期随访未发现非那雄胺后综合征的证据。
  • 22种潜在PFS相关症状均与治疗组无显著关联。
  • 个案报告可能反映老年人群症状普遍性及报告偏倚。

核心结论

  • 在最大规模的非那雄胺安慰剂对照研究中,长期随访不支持「非那雄胺后综合征」概念。
  • 现有个案报告可能归因于老年人群中症状的普遍性及报告偏倚。

研究设计与样本

  • PCPT是一项大规模随机安慰剂对照试验,受试者记录与Medicare理赔数据链接。
  • 18,880名合格受试者中15,122名链接到Medicare,14,239名有至少一年连续覆盖。
  • 从研究注册至Medicare入组结束的中位随访为20年,共267,983人年随访。

主要发现

  • 在22种潜在归因于PFS的病症中,无一与治疗组存在统计学显著关联。
  • 分析比较了既往非那雄胺使用与匹配安慰剂,并调整了年龄、种族、BMI和前列腺癌家族史。

临床怎么用

  • 临床咨询时可告知患者长期安慰剂对照数据未支持非那雄胺后综合征。
  • 对于个案报告的症状,应考虑老年人群普遍性及报告偏倚的可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate Post-Finasteride Syndrome, a broad range of symptoms reported in case reports and case series among patients who have received finasteride, a five-alpha reductase inhibitor. We evaluate the frequency of these symptoms in the Prostate Cancer Prevention Trial (PCPT), a large-scale randomized, placebo-controlled trial of finasteride. METHODS: Records of subjects enrolled in the PCPT were linked to Medicare claims data. Medicare claims were queried for a group of 22 conditions potentially attributed to PFS, including sexual and cognitive symptoms. Logistic regression and Cox regression analyses, comparing former finasteride use to matched placebo, were adjusted for age, race, BMI, and family history of prostate cancer. RESULTS: Of 18,880 eligible subjects, 15,122 were linked to Medicare; of these 14,239 had one or more years of continuous coverage. Median follow-up from study registration to end of Medicare enrollment was 20 years with 267,983 person-years of follow-up. Of the 22 conditions potentially related to PFS, none had a statistically significant association with treatment arm. CONCLUSION: In the largest placebo-controlled study of the five-alpha-reductase inhibitor, finasteride, long-term follow-up does not support the concept of a "Post-Finasteride Syndrome." The anecdotal reports to date are likely related to the ubiquitous nature of these symptoms in an aging population and reporting bias.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Till C, Tangen CM, Goodman P, et al. No Evidence of Post-Finasteride Syndrome in 267,983 Person-Years Follow-up in the Prostate Cancer Prevention Trial. Urology. 2026. PMID: 42628582. doi:10.1016/j.urology.2026.08.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。